Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

XLV offers a rare combination of stability and growth potential through its diverse investments in the healthcare sector, ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

The donation "fiasco," as it was called by one trustee, still loomed large even as the board rallied around President Larry ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...